Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases

This study has been completed.
Information provided by:
Merck Sharp & Dohme Corp. Identifier:
First received: August 30, 2005
Last updated: November 19, 2009
Last verified: November 2009

Antiproteinuric Efficacy of Losartan Potassium in Patients with Non-Diabetic Proteinuric Renal Diseases.

Condition Intervention Phase
Renal Disorder
Drug: MK0954, losartan potassium/Duration of Treatment: 20 weeks
Drug: Comparator: amlodipine / Duration of Treatment: 20 weeks
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Parallel, Double Blind Study of Losartan Versus Amlodipine in Patients With Mild to Moderate Hypertension and Chronic Nondiabetic Proteinuric Nephropathy: Evaluation of the Effect on Proteinuria and on the Plasmatic Levels of Growth Factors (TGFß and VEGF)

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • 24h proteinuria

Secondary Outcome Measures:
  • Changes in the plasma and urinary levels of TGF-beta

Enrollment: 97
Study Start Date: February 2000
Study Completion Date: March 2001

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males or females at least 18 years of age with non-diabetic proteinuric renal diseases
  Contacts and Locations
Please refer to this study by its identifier: NCT00140985

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

No publications provided

Responsible Party: Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc. Identifier: NCT00140985     History of Changes
Other Study ID Numbers: 2005_058, MK0954-213
Study First Received: August 30, 2005
Last Updated: November 19, 2009
Health Authority: Spain: Ministry of Health

Additional relevant MeSH terms:
Kidney Diseases
Urologic Diseases
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Cardiovascular Agents
Therapeutic Uses
Vasodilator Agents
Antihypertensive Agents
Anti-Arrhythmia Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists processed this record on April 15, 2014